Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Change in Accured Expenses (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Change in Accured Expenses for 5 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 241.93% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$962000.0, a 152.94% decrease, with the full-year FY2024 number at $3.5 million, up 179.7% from a year prior.
  • Change in Accured Expenses was -$1.2 million for Q3 2025 at Werewolf Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q3 2022 to a low of -$3.9 million in Q2 2023.
  • A 5-year average of -$78777.8 and a median of $409500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 15053.33% in 2022, then plummeted 373.42% in 2024.
  • Werewolf Therapeutics' Change in Accured Expenses stood at -$30000.0 in 2021, then crashed by 5336.67% to -$1.6 million in 2022, then skyrocketed by 158.43% to $953000.0 in 2023, then surged by 171.88% to $2.6 million in 2024, then plummeted by 146.51% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Change in Accured Expenses are -$1.2 million (Q3 2025), $1.0 million (Q2 2025), and -$3.4 million (Q1 2025).